Novel Lipid Mediators May Play Role in Omega-3 PUFA Effects

Share this content:
Novel Lipid Mediators May Play Role in Omega-3 PUFA Effects
Novel Lipid Mediators May Play Role in Omega-3 PUFA Effects

FRIDAY, June 24, 2016 (HealthDay News) -- Novel lipid mediators may be involved in the beneficial effects associated with omega-3 polyunsaturated fatty acids (PUFAs) in obesity, according to a study published online June 16 in Diabetes.

Noting that dysregulation of metabolic and endocrine functions of white adipose tissue (WAT), together with low-grade inflammation of the tissue in obesity, contributes to type 2 diabetes, Ondrej Kuda, Ph.D., from the Czech Academy of Sciences in Prague, and colleagues conducted experiments in mice and overweight/obese patients with type 2 diabetes. They elucidated the structures of novel members of fatty acid esters of hydroxy fatty acids (FAHFAs), derived from docosahexaenoic acid (DHA) and linoleic acid, which were identified in serum and WAT after supplementation with omega-3 PUFA.

The researchers found that the FAHFAs contained DHA esterified to 9- and 13-hydroxyoctadecadienoic acid (HLA) or 14-hydroxydocosahexaenoic acid (HDHA) (9-DHAHLA, 13-DHAHLA, and 14-DHAHDHA). Synthesis of these compounds by adipocytes occurred at concentrations comparable to those of protectins and resolvins derived from DHA in WAT. Anti-inflammatory and pro-resolving properties were seen for 13-DHAHLA, together with a reduction in macrophage activation by lipopolysaccharide and enhanced phagocytosis of zymosan particles.

"Our results document the existence of novel lipid mediators, which are involved in the beneficial anti-inflammatory effects attributed to omega-3 PUFA, in both mice and humans," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

FDA Approves First Generic Under-the-Tongue Suboxone

FDA Approves First Generic Under-the-Tongue Suboxone

May only be prescribed by Drug Addiction Treatment Act-certified prescribers

Kellogg's Honey Smacks Cereal Recalled Due to Salmonella Risk

Kellogg's Honey Smacks Cereal Recalled Due to <i>Salmonella</i> ...

Twenty-four people have been hospitalized, but no deaths have been reported

Portable Music Player Use Linked to Hearing Loss in Children

Portable Music Player Use Linked to Hearing Loss ...

Increased odds of high-frequency hearing loss with portable music player use

is free, fast, and customized just for you!




Already a member?

Sign In Now »